CCHR Int5h
The ADHD Epidemic: How Profit, Not Science, Drives the Surge in Diagnoses
A Federal Investigation Has Launched into the Mass Labeling and Drugging of America’s Children, especially for ADHD. By CCHR InternationalThe Mental Health Industry WatchdogFebruary 21, 2025 • The ...
CAPLYTA’S Strong Market Adoption Propels Its Rise As A Leading Antipsychotic Therapy | Delveinsight
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
ENDPOINTS NEWS11h
Te­va launch­es Ste­lara biosim­i­lar at 85% dis­count as wider field emerges
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
Le Lézard18h
Teva and Alvotech Announce SELARSDItm (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...